My watch list
my.chemeurope.com  
Login  

Ambrisentan



Ambrisentan
Systematic (IUPAC) name
2-(4,6-dimethylpyrimidin-2-yl)oxy-3-methoxy-
3,3-diphenyl-propanoic acid
Identifiers
CAS number 177036-94-1
ATC code C02KX02
PubChem 197712
Chemical data
Formula C22H22N2O4 
Mol. mass 378.421 g/mol
SMILES search in eMolecules, PubChem
Pharmacokinetic data
Bioavailability Undetermined
Protein binding 99%
Metabolism  ?
Half life 15 hours (terminal)
Excretion  ?
Therapeutic considerations
Pregnancy cat.

X(US) May cause harm to fetus

Legal status

-only(US)

Routes Oral

Ambrisentan (U.S. trade name Letairis) is a drug being researched for use in the treatment of pulmonary hypertension.

Additional recommended knowledge

It functions as an endothelin receptor antagonist, and is selective for the type A endothelin receptor (ETA).[1]

Ambrisentan was approved for sale by the U.S. Food and Drug Administration (FDA) on June 15 2007 for the once-daily treatment of pulmonary arterial hypertension.[2][3][4] The Marketing Authorisation Application is under review by the European Medicines Agency.[5] Ambrisentan had previously been designated an orphan drug by both the FDA and the European Commission, in August 2004 and May 2005 respectively.[6]

References

  1. ^ Vatter H, Seifert V (2006). "Ambrisentan, a non-peptide endothelin receptor antagonist". Cardiovasc Drug Rev 24 (1): 63-76. PMID 16939634.
  2. ^ Pollack, Andrew. "Gilead’s Drug Is Approved to Treat a Rare Disease", New York Times, 2007-06-16. Retrieved on 2007-05-25. 
  3. ^ Gilead Sciences (2007-06-15). "U.S. Food and Drug Administration Approves Gilead's Letairis Treatment of Pulmonary Arterial Hypertension". Press release. Retrieved on 2007-06-16.
  4. ^ Food and Drug Administration (2007-06-15). "FDA Approves New Orphan Drug for Treatment of Pulmonary Arterial Hypertension". Press release. Retrieved on 2007-06-22.
  5. ^ Gilead Sciences (2007-03-23). "Marketing Authorisation Application for Ambrisentan Validated by European Medicines Agency". Press release. Retrieved on 2007-06-16.
  6. ^ Waknine, Yael (2005-05-09). International Approvals: Ambrisentan, Oral-lyn, Risperdal. Medscape. Retrieved on 2007-06-16.


 
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Ambrisentan". A list of authors is available in Wikipedia.
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE